Antipruritic effect of Pimecrolimus Cream %1 in Patients with Chronic Renal Failure

Assessment of Antipruritic effect of Pimecrolimus Cream %1 in Patients with Chronic Renal Failure referring to Ahwaz Imam Khomeini Hospital-Iran dyalisis center during 2009.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201011015069N1

Enrollment

Registered

2011-04-18

Start date

2010-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End stage renal disease. ?????? ????? ????? ???????

Interventions

Intervention 1: Pimecrolimus cream 1%, 30 gram twice a day for 8 weeks after dialysis in intervention group. Intervention 2: Placebo cream (Emolient), 30 garm for 8 weeks twice a day after dialysis i

Treatment - Drugs

Pimecrolimus cream 1%, 30 gram twice a day for 8 weeks after dialysis in intervention group

Placebo cream (Emolient), 30 garm for 8 weeks twice a day after dialysis in control group

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: known case of chronic renal failure, between 18 and 60 years old, not using of antihistamines or other anti-pruritus drugs during last 3 months. Exclusion criteria:the presence of other known pruritic diseases.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pruritus. Timepoint: before intervention and every week for eight weeks. Method of measurement: Visual Analogue Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaman Moosavian

Gachsaran Islamic Azad University

info@iaug.ac.ir+98 74 2333 4607

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026